Amplification of CDK6 and deletion of CDK inhibitor 2A/B (CDKN2A/B) genes are frequently found in GBM patients (~ 86%), specifically in classical and mesenchymal subtypes [119]. The gene discussed is CDKN2A; the disease is glioblastoma.